Clinical Trial Update: A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder [Phase 2]

View source ↗

Summary

AbbVie completed a Phase 2 study evaluating the efficacy, safety, and tolerability of darigabat in participants with panic disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Panic Disorder

Drugs mentioned

• Darigabat (darigabat)

Snippet

Sponsor: AbbVie | Conditions: Panic Disorder | Phase 2 | Status: COMPLETED